Abits
ABTS
Bakkt Holdings
BKKT
Riot Platforms
RIOT
Canaan
CAN
CATHEDRA BITCOIN INC
CBTTF
US Stock MarketDetailed Quotes
FULC Fulcrum Therapeutics
- 3.960
- -0.070-1.74%
Close Dec 13 16:00 ET
- 3.960
- 0.0000.00%
Post 16:01 ET
213.60MMarket Cap-13.66P/E (TTM)
4.210High3.960Low478.27KVolume4.020Open4.030Pre Close1.92MTurnover1.46%Turnover RatioLossP/E (Static)53.94MShares13.70052wk High0.83P/B129.90MFloat Cap2.86052wk Low--Dividend TTM32.80MShs Float33.098Historical High--Div YieldTTM6.20%Amplitude2.250Historical Low4.007Avg Price1Lot Size
Trending US Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Fulcrum Therapeutics Stock Forum
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Fulcrum Therapeutics (NASDAQ: FULC) announced that its Phase 3 REACH trial for losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) failed to meet its primary endpoint. The trial showed no significant improvement in relative surface area (RSA) compared to placebo at week 48. Secondary endpoints also failed to ...
Fulcrum Therapeutics Enters Into a Collaboration and License Agreement With Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
No comment yet